Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions
Study Details
Study Description
Brief Summary
The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and GlaxoSmithKline (Augmentin®) 400 mg amoxicillin (as the trihydrate) and 57 mg clavulnic acid (as the potassium salt) chewable tablet, following administration of 2 tablet dose under fasting conditions
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The study was conducted as an open-label, randomized, 2-way crossover study to compare the single-dose relative bioavailability of Ranbaxy and GlaxoSmithKline (Augmentin® 400 mg) amoxicillin (as the trihydrate)/57 mg clavulanic acid (as the potassium salt) chewable tablet, following administration of 2 tablet dose under fasting conditions A total of 40 subjects (22 males and 18 females) were included in this study, of which 39 (21 males and 18 females) finished the study according to the protocol.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1 amoxicillin 400mg + clovalunic acid 57.5mg tablets of Ranbaxy |
Drug: amoxicillin 400mg + clovalunic acid 57.5mg tablets
|
| Active Comparator: 2 Augmentin® tablets of glaxosmithkline |
Drug: amoxicillin 400mg + clovalunic acid 57.5mg tablets
|
Outcome Measures
Primary Outcome Measures
- Bioequivalence []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy adult male or female volunteers, 18-55 years of age
-
Weighing at least 52 kg for males and 45 kg for females and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983);
-
Medically healthy subjects with clinically normal laboratory profiles;
-
Females of childbearing potential should either be sexually inactive (abstinent) for 14 days prior to the study and throughout the study or be using one of the following acceptable birth control methods:
surgically sterile (bilateral tubal ligation, hysterectomy bilateral oophorectomy) 6 months minimum; IUD in place for at least 3 months; barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the start of the study and .throughout the study; surgical sterilization of the partner (vasectomy for 6 months minimum); hormonal contraceptives for at least 3 months prior to the start of the study. Other birth control methods may be deemed acceptable. Postmenopausal women with amenorrhea for at least 2 years will be eligible;
- Voluntarily consent to participate in the study.
Exclusion Criteria:
Subject candidates must not be enrolled in the study if they meet any of the following criteria:
-
History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic,gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.
-
In addition, history or presence of:
alcoholism or drug abuse within the past 2 years; hypersensitivity or idiosyncratic reaction to antibiotics, especially penicillins, cephalosporins and amoxicillin and/or clavulanic acid
-
Female subjects who are pregnant or lactating.
-
Subjects who have been on an abnormal diet (for whatever reason) during the 30 days prior to the first dose.
-
Subjects who have made a donation (standard donation amount or more) of blood or blood products (with the exception of plasma as noted below) within 30 days prior to the study.
-
Subjects who have made a plasma donation within 7 days prior to the study
-
Subjects who have participated in another clinical trial within 30 days prior to the first dose.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | MDS Pharma Services | Phoenix | Arizona | United States | 85044 |
Sponsors and Collaborators
- Ranbaxy Laboratories Limited
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- AA02872